^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

TEST:
4D Lifetest™ Lung Dx

Company:
4D Lifetec
Type:
CE Marked
Evidence

News

5ms
4D Lifetec secures CHF 23.3 Mio in a share and investment deal with Xlife Sciences opening new horizons in using AI and digital health in early cancer detection. (4D Lifetec Press Release)
"In a significant financial milestone, Xlife Sciences AG invests CHF 23.3 million in 4D Lifetec AG, acquiring a 20% stake in the company. With the agreement signed today, Xlife Sciences is not only bringing in a direct cash investment, but also an AI software developed specifically for 4D Lifetec, which will massively expand the functionality of the 4D Lifetest™ in the field of digital health. The strategic investment marks a significant turning point in the healthcare industry as it combines financial strength with cutting-edge technology to revolutionize early cancer detection."
Financing
|
4D Lifetest™ Lung Dx
over1year
4D Lifetec, Molecular Diagnostics Group ink partnership for liquid biopsy assay (Genomeweb)
"Swiss firm 4D Lifetec...has forged a partnership with the Molecular Diagnostics Group to produce and automate 4D Lifetec's cancer assays and develop the tests for high-throughput screening...The agreement covers 4D Lifetec's 4D Lifetest series of early cancer assays, including the 4D Lifetest Lung Dx the firm launched in Europe this year for detection of early-stage lung cancer and its CE IVD-marked 4D Lifetest assays for breast, prostate, and colon cancers..."
Licensing / partnership
|
4D Lifetest™ Lung Dx